Vaccines
Senate Hearing for RFK Jr. Amid Strong Public Support for Vaccine Access
RFK Jr., Senate hearing, vaccine access, public support, FDA-approved vaccines, Department of Health and Human Services nomination
RFK Jr. Faces Intense Scrutiny in Senate Confirmation Hearings for HHS Secretary
Robert F. Kennedy Jr., Senate confirmation hearings, Health and Human Services Secretary, Trump nominee, vaccine stance, Republican doubts
RFK Jr.’s Financial Ties to Gardasil Litigation Spark Conflict-of-Interest Concerns
RFK Jr., Gardasil, Merck, Conflict of Interest, Vaccine Litigation, HHS Secretary Nomination
HHS Awards Moderna $590 Million to Expedite Bird Flu Vaccine Development
Moderna, HHS, Bird Flu Vaccine, Avian Influenza, mRNA Vaccine, Pandemic Preparedness
Pharmaceutical CEOs Emphasize Transparency to Counter Anti-Vaccine Sentiment in the US
Anti-vaccine movement, Transparency, GSK, Sanofi, Vaccine hesitancy, Public health
Moderna Slashes 2025 Revenue Forecast, Expands Cost-Cutting Measures Amid Vaccine Sales Decline
Moderna, 2025 revenue forecast, cost-cutting measures, vaccine sales decline, COVID-19 vaccine market competition, falling vaccination rates.
FDA Mandates Guillain-Barré Syndrome Warning for Pfizer and GSK RSV Vaccines
RSV vaccines, Guillain-Barré syndrome, FDA warning, Pfizer, GSK, Abrysvo, Arexvy
WuXi Biologics Divests Irish Vaccine Facility to Merck for $500 Million Amid Strategic Shift
WuXi Biologics, Merck, vaccine manufacturing facility, Dundalk, Ireland, asset sale, strategic shift, regulatory changes, Biosecure Act
Moderna CEO Reflects on 2024 Challenges and Advances in Shareholder Letter
Moderna, shareholder letter, 2024 review, RSV vaccine, COVID-19 vaccine, mRNA medicines, Stéphane Bancel
Merck Acquires WuXi Biologics’ Irish Vaccine Facility in $500M Deal
Merck, WuXi Biologics, vaccine facility, Ireland, $500M deal, pharmaceutical manufacturing